280 related articles for article (PubMed ID: 35604836)
1. Optimal sample size determination for single-arm trials in pediatric and rare populations with Bayesian borrowing.
Ji Z; Lin J; Lin J
J Biopharm Stat; 2022 Jul; 32(4):529-546. PubMed ID: 35604836
[TBL] [Abstract][Full Text] [Related]
2. Empirical bayes approach for dynamic bayesian borrowing for clinical trials in rare diseases.
Sebastien B
J Pharmacokinet Pharmacodyn; 2023 Dec; 50(6):495-499. PubMed ID: 37148459
[TBL] [Abstract][Full Text] [Related]
3. Simulating and reporting frequentist operating characteristics of clinical trials that borrow external information: Towards a fair comparison in case of one-arm and hybrid control two-arm trials.
Kopp-Schneider A; Wiesenfarth M; Held L; Calderazzo S
Pharm Stat; 2024; 23(1):4-19. PubMed ID: 37632266
[TBL] [Abstract][Full Text] [Related]
4. Bayesian sample size determination in basket trials borrowing information between subsets.
Zheng H; Grayling MJ; Mozgunov P; Jaki T; Wason JMS
Biostatistics; 2023 Oct; 24(4):1000-1016. PubMed ID: 35993875
[TBL] [Abstract][Full Text] [Related]
5. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
Teramukai S; Daimon T; Zohar S
Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
[TBL] [Abstract][Full Text] [Related]
6. Bayesian clinical trial design using historical data that inform the treatment effect.
Psioda MA; Ibrahim JG
Biostatistics; 2019 Jul; 20(3):400-415. PubMed ID: 29547966
[TBL] [Abstract][Full Text] [Related]
7. Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.
Hupf B; Bunn V; Lin J; Dong C
Stat Med; 2021 Jun; 40(14):3385-3399. PubMed ID: 33851441
[TBL] [Abstract][Full Text] [Related]
8. Comparative Study of Bayesian Information Borrowing Methods in Oncology Clinical Trials.
Su L; Chen X; Zhang J; Yan F
JCO Precis Oncol; 2022 Mar; 6():e2100394. PubMed ID: 35263169
[TBL] [Abstract][Full Text] [Related]
9. Incorporating historical two-arm data in clinical trials with binary outcome: A practical approach.
Feißt M; Krisam J; Kieser M
Pharm Stat; 2020 Sep; 19(5):662-678. PubMed ID: 32227680
[TBL] [Abstract][Full Text] [Related]
10. Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.
Wang Y; Travis J; Gajewski B
BMC Med Res Methodol; 2022 Apr; 22(1):118. PubMed ID: 35448963
[TBL] [Abstract][Full Text] [Related]
11. A group-sequential randomized trial design utilizing supplemental trial data.
Kotalik A; Vock DM; Hobbs BP; Koopmeiners JS
Stat Med; 2022 Feb; 41(4):698-718. PubMed ID: 34755388
[TBL] [Abstract][Full Text] [Related]
12. Propensity score-integrated Bayesian prior approaches for augmented control designs: a simulation study.
Wang X; Suttner L; Jemielita T; Li X
J Biopharm Stat; 2022 Jan; 32(1):170-190. PubMed ID: 34939894
[TBL] [Abstract][Full Text] [Related]
13. Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma.
Hirakawa A; Nishikawa T; Yonemori K; Shibata T; Nakamura K; Ando M; Ueda T; Ozaki T; Tamura K; Kawai A; Fujiwara Y
Ther Innov Regul Sci; 2018 May; 52(3):334-338. PubMed ID: 29714533
[TBL] [Abstract][Full Text] [Related]
14. Bayesian sample size determination in a three-arm non-inferiority trial with binary endpoints.
Tang N; Yu B
J Biopharm Stat; 2022 Sep; 32(5):768-788. PubMed ID: 35213275
[TBL] [Abstract][Full Text] [Related]
15. Bayesian design of biosimilars clinical programs involving multiple therapeutic indications.
Psioda MA; Hu K; Zhang Y; Pan J; Ibrahim JG
Biometrics; 2020 Jun; 76(2):630-642. PubMed ID: 31631321
[TBL] [Abstract][Full Text] [Related]
16. Bayesian borrowing from historical control data in a vaccine efficacy trial.
Peng L; Jin J; Chambonneau L; Zhao X; Zhang J
Pharm Stat; 2023; 22(5):815-835. PubMed ID: 37226586
[TBL] [Abstract][Full Text] [Related]
17. Utility of propensity score-based Bayesian borrowing of external adult data in pediatric trials: A pragmatic evaluation through a case study in acute lymphoblastic leukemia (ALL).
Majumdar A; Rothwell R; Reaman G; Ahlberg C; Roy P
J Biopharm Stat; 2023 Nov; 33(6):737-751. PubMed ID: 36600441
[TBL] [Abstract][Full Text] [Related]
18. On the feasibility of pediatric dose-finding trials in small samples with information from a preceding trial in adults.
Zocholl D; Wiesenfarth M; Rauch G; Kopp-Schneider A
J Biopharm Stat; 2022 Sep; 32(5):652-670. PubMed ID: 34962850
[TBL] [Abstract][Full Text] [Related]
19. A BAYESIAN ADAPTIVE TWO-STAGE DESIGN FOR PEDIATRIC CLINICAL TRIALS.
Psioda MA; Xue X
J Biopharm Stat; 2020 Nov; 30(6):1091-1108. PubMed ID: 33019841
[TBL] [Abstract][Full Text] [Related]
20. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
Moatti M; Chevret S; Zohar S; Rosenberger WF
Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
